EGFR and non-small cell lung carcinoma: Therefore, the dependency on EGFR signaling at the baseline might be critical for predicting osimertinib response after acquiring resistance to initial EGFR-TKIs in NSCLC patients with the EGFR-T790M mutation (Figure 2D).